MEDP
Medpace Holdings, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -6.2% ·
share flow +16.7% ·
net new positions -6.7%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 131 | -10 | 16.81M | $8.90B | +3 | −12 |
| Q1 2026 | 143 | -2 | 15.75M | $7.54B | +5 | −8 |
| Q4 2025 | 145 | 0 | 17.01M | $9.56B | +1 | — |
| Q3 2025 | 22 | 0 | 10.56M | $5.42B | +1 | −2 |
| Q2 2025 | 20 | +1 | 9.67M | $3.03B | +1 | — |
| Q1 2025 | 16 | -1 | 3.77M | $1.14B | — | −1 |
| Q4 2024 | 17 | +1 | 4.06M | $1.35B | +1 | — |
| Q3 2024 | 15 | -1 | 3.56M | $1.19B | — | −1 |
| Q2 2024 | 16 | — | 3.05M | $1.26B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 628.05K | +7.6% | $209.88M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 628.05K | +7.6% | $209.88M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Renaissance Technologies ✦ | 492.49K | +11.0% | $164.39M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 4 | Capital World Investors ✦ | 438.37K | +71178.9% | $146.33M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 415.25K | +36.0% | $138.61M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 415.25K | +36.0% | $138.61M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 365.75K | +17.7% | $120.79M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 365.75K | +17.7% | $120.79M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 365.75K | +17.7% | $120.79M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 10 | Norges Bank ✦ (passive) | 235.50K | -15.8% | $78.61M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Arrowstreet Capital ✦ | 217.65K | -8.3% | $72.65M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 208.54K | -30.5% | $69.61M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 208.54K | -30.5% | $69.61M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 146.03K | +18.0% | $48.74M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 131.53K | -14.8% | $43.91M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 131.53K | -14.8% | $43.91M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 124.40K | +6.9% | $41.52M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | Millennium Management ✦ | 113.08K | +3.0% | $37.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 16.25K | +68.3% | $5.42M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 20 | Baillie Gifford ✦ | 14.88K | +175.6% | $4.97M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 21 | Baillie Gifford ✦ | 14.88K | +175.6% | $4.97M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 22 | Gotham Asset Management ✦ | 8.21K | +39.5% | $2.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Point72 Asset Management | $25.71M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 724 holders, 23.89M shares, $10.71B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director, 10% owner · 1.98K sh · $1.23M
Officer, Director, 10% owner · 13.99K sh · $8.74M
Officer · 3.40K sh · $2.13M
Officer, Director, 10% owner · 27.17K sh · $16.81M
Director · 7.28K sh · $4.41M
Officer, Director, 10% owner · 15.61K sh · $9.47M
Director · 5.00K sh · $3.04M
Officer, Director, 10% owner · 458 sh · $274,979
Officer, Director, 10% owner · 11.37K sh · $6.84M
Director · 1.14K sh · $690,122
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology